复方磺胺甲噁唑与阿奇霉素治疗尼泊尔未分化发热性疾病:随机对照试验研究方案
本研究为在尼泊尔开展的平行组、双盲、1:1随机对照试验,比较复方磺胺甲噁唑与阿奇霉素治疗未分化发热性疾病(UFI)的效果。研究对象为2至65岁、发热无明确病灶至少4天的患者,主要终点为退热时间、治疗失败、至治疗失败时间及不良事件,估计样本量为330例。
要点
- 在尼泊尔开展双盲随机对照试验,比较复方磺胺甲噁唑与阿奇霉素治疗未分化发热性疾病。
- 纳入2至65岁、发热无明确病灶至少4天且符合其他研究标准并愿意签署书面知情同意书的患者。
- 主要终点为退热时间、治疗失败、至治疗失败时间及不良事件,估计样本量为330例。
核心结论
- 阿奇霉素和复方磺胺甲噁唑在尼泊尔均可获得并广泛用于治疗未分化发热性疾病,因此明确治疗肠热症和其他未分化发热性疾病的更优口服抗菌药物很重要,尤其是在氟喹诺酮类耐药肠热症的背景下。
研究设计与样本
- 本研究为平行组、双盲、1:1随机对照试验,在尼泊尔比较复方磺胺甲噁唑与阿奇霉素治疗未分化发热性疾病。
- 研究对象为2至65岁、发热无明确病灶至少4天、符合其他研究标准并愿意提供书面知情同意书的患者。
- 患者随机接受阿奇霉素20 mg/kg/天(最大1000 mg/天)单次每日给药加相同安慰剂,或复方磺胺甲噁唑60 mg/kg/天(最大3000 mg/天)分两次给药,疗程7天。
- 估计样本量为330例,主要分析人群为所有随机化人群,并将在血培养确诊肠热症患者和培养阴性患者中重复亚组分析。
关键数值与推荐
- 阿奇霉素剂量为20 mg/kg/天(最大1000 mg/天),单次每日给药,疗程7天。
- 复方磺胺甲噁唑剂量为60 mg/kg/天(最大3000 mg/天),分两次给药,疗程7天。
- 主要终点为退热时间、治疗失败、至治疗失败时间及不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Undifferentiated febrile illness (UFI) includes typhoid and typhus fevers and generally designates fever without any localizing signs. UFI is a great therapeutic challenge in countries like Nepal because of the lack of available point-of-care, rapid diagnostic tests. Often patients are empirically treated as presumed enteric fever. Due to the development of high-level resistance to traditionally used fluoroquinolones against enteric fever, azithromycin is now commonly used to treat enteric fever/UFI. The re-emergence of susceptibility of Salmonella typhi to co-trimoxazole makes it a promising oral treatment for UFIs in general. We present a protocol of a randomized controlled trial of azithromycin versus co-trimoxazole for the treatment of UFI. METHODS/DESIGN: This is a parallel-group, double-blind, 1:1, randomized controlled trial of co-trimoxazole versus azithromycin for the treatment of UFI in Nepal. Participants will be patients aged 2 to 65 years, presenting with fever without clear focus for at least 4 days, complying with other study criteria and willing to provide written informed consent. Patients will be randomized either to azithromycin 20 mg/kg/day (maximum 1000 mg/day) in a single daily dose and an identical placebo or co-trimoxazole 60 mg/kg/day (maximum 3000 mg/day) in two divided doses for 7 days. Patients will be followed up with twice-daily telephone calls for 7 days or for at least 48 h after they become afebrile, whichever is later; by home visits on days 2 and 4 of treatment; and by hospital visits on days 7, 14, 28 and 63. The endpoints will be fever clearance time, treatment failure, time to treatment failure, and adverse events. The estimated sample size is 330. The primary analysis population will be all the randomized population and subanalysis will be repeated on patients with blood culture-confirmed enteric fever and culture-negative patients. DISCUSSION: Both azithromycin and co-trimoxazole are available in Nepal and are extensively used in the treatment of UFI. Therefore, it is important to know the better orally administered antimicrobial to treat enteric fever and other UFIs especially against the background of fluoroquinolone-resistant enteric fever. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02773407 . Registered on 5 May 2016.
引用
- Pokharel S, Basnyat B, Arjyal A, et al. Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28969659. doi:10.1186/s13063-017-2199-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。